Lung injury following cardiopulmonary bypass: a clinical update.
Cardiopulmonary bypass (CPB)
lung injury
systemic inflammatory response syndrome (SIRS)
Journal
Expert review of cardiovascular therapy
ISSN: 1744-8344
Titre abrégé: Expert Rev Cardiovasc Ther
Pays: England
ID NLM: 101182328
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
pubmed:
22
11
2022
medline:
15
12
2022
entrez:
21
11
2022
Statut:
ppublish
Résumé
Cardiopulmonary bypass (CPB) is an integral component of cardiac surgery; however, one of its most critical complications is acute lung injury induced by multiple factors including systemic inflammatory response. The objective of this review is to investigate the multiple factors that can lead to CPB-induced lung injury. These include contact of blood components with the artificial surface of the CPB circuit, local and systemic inflammatory response syndrome (SIRS), lung ischemia/re-perfusion injury, arrest of ventilation, and circulating endotoxins. We also focus on possible interventions to curtail the negative impact of CPB, such as off-pump surgery, impregnation of the circuit with less biologically active substances, leukocyte depletion filters and ultrafiltration, and pharmacological agents such as steroids and aprotinin. Although many aspects of CPB are proposed to contribute to lung injury, its overall role is still not clear. Multiple interventions have been introduced to reduce the risk of pulmonary dysfunction, with many of these interventions having shown promising results, significantly attenuating inflammatory mediators and improving post-operative outcome. However, since lung injury is multifactorial and affected by inextricably linked components, multiple interventions tackling each of them is required.
Identifiants
pubmed: 36408601
doi: 10.1080/14779072.2022.2149492
doi:
Substances chimiques
Inflammation Mediators
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM